LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.50
−0.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.4M | 19.1M | — | — | 15.0M |
| Cost of Revenue | 2.4M | 705.0K | 58.0K | — | — |
| Gross Profit | 9.9M | 18.4M | (58.0K) | — | 15.0M |
| Operating Expenses | |||||
| R&D Expense | — | 18.7M | 29.8M | 59.5M | 21.1M |
| SG&A Expense | 159.6M | 90.9M | 28.8M | 12.9M | 4.4M |
| General & Admin Expense | 39.4M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 159.6M | 109.5M | 58.6M | 72.4M | 25.5M |
| Cost and Expenses | 162.0M | 110.2M | 58.6M | 72.4M | 25.5M |
| Operating Income (EBIT) | (149.7M) | (91.1M) | (58.6M) | (72.4M) | (10.5M) |
| Non-Operating | |||||
| Interest Income | 9.9M | 9.8M | 8.6M | 2.2M | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 9.9M | 9.8M | 8.6M | 2.2M | — |
| Other Non-Op Income/Expense | 9.4M | 9.5M | 8.8M | 2.3M | 19.0K |
| Non-Operating Income (excl Interest) | (7.5M) | (9.5M) | (8.8M) | (2.3M) | (19.0K) |
| EBT (Pre-Tax Income) | (140.3M) | (81.6M) | (49.8M) | (70.1M) | (10.5M) |
| Income Tax Expense | 5.0K | 502.0K | 1.0K | (179.0K) | 347.0K |
| Bottom Line | |||||
| Net Income | (140.3M) | (82.1M) | (49.8M) | (70.0M) | (10.8M) |
| Earnings from Cont. Ops | (140.3M) | (82.1M) | (49.8M) | (70.0M) | (10.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (140.3M) | (82.1M) | (49.8M) | (70.0M) | (10.8M) |
| Per Share | |||||
| Basic EPS | ($4.49) | ($2.85) | ($2.34) | ($15.30) | ($12.89) |
| Diluted EPS | ($4.49) | ($2.85) | ($2.34) | ($15.30) | ($12.89) |
| Revenue Per Share | $0.39 | $0.66 | $0.00 | $0.00 | $1.91 |
| Shares | |||||
| Basic Shares Outstanding | 31.4M | 28.8M | 21.3M | 8.1M | 7.8M |
| Diluted Shares Outstanding | 31.4M | 28.8M | 21.3M | 8.1M | 7.8M |
| Profitability Metrics | |||||
| EBITDA | (141.9M) | (81.3M) | (49.7M) | (70.1M) | (10.5M) |
| D&A | 328.0K | 287.0K | 58.0K | 15.0K | 8.0K |
| EBIT | (142.2M) | (81.6M) | (49.8M) | (70.1M) | (10.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026